Rice Hall James & Associates LLC trimmed its holdings in Senseonics Holdings Inc (NYSEAMERICAN:SENS) by 18.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,620 shares of the company’s stock after selling 36,000 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Senseonics were worth $761,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of SENS. Gilder Gagnon Howe & Co. LLC bought a new position in Senseonics in the 2nd quarter worth approximately $74,936,000. BlackRock Inc. grew its holdings in Senseonics by 1,958.6% in the 2nd quarter. BlackRock Inc. now owns 3,811,007 shares of the company’s stock worth $15,664,000 after buying an additional 3,625,877 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new position in Senseonics in the 3rd quarter worth approximately $14,703,000. PointState Capital LP bought a new position in Senseonics in the 2nd quarter worth approximately $10,970,000. Finally, OppenheimerFunds Inc. bought a new position in Senseonics in the 2nd quarter worth approximately $7,926,000. 30.66% of the stock is owned by institutional investors and hedge funds.
Shares of NYSEAMERICAN SENS opened at $3.67 on Tuesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.93 and a quick ratio of 2.81. Senseonics Holdings Inc has a 1 year low of $2.41 and a 1 year high of $5.29.
A number of equities analysts recently issued reports on the company. BTIG Research reissued a “buy” rating and issued a $6.00 price objective on shares of Senseonics in a report on Thursday, August 9th. Dougherty & Co assumed coverage on Senseonics in a report on Friday, August 24th. They issued a “buy” rating and a $6.00 price objective for the company. Six research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $6.00.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Read More: Asset Allocation and Your Retirement
Want to see what other hedge funds are holding SENS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Senseonics Holdings Inc (NYSEAMERICAN:SENS).
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.